샘플 요청 목록

 카트 문의
시장보고서
상품코드
1792798

세계의 나노바디 시장

Nanobodies
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 379 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

나노바디 세계 시장은 2030년까지 15억 달러에 달할 전망

2024년에 5억 6,100만 달러로 추정되는 나노바디 세계 시장은 분석 기간인 2024-2030년에 CAGR 18.0%로 성장하여 2030년에는 15억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 단특이적 유형은 CAGR 19.5%를 기록하며 분석 기간 종료시에는 11억 달러에 달할 것으로 예측됩니다. 다특이적 유형 부문의 성장률은 분석 기간 동안 CAGR 14.8%로 추정됩니다.

미국 시장은 1억 5,280만 달러로 추정, 중국은 CAGR 24.0%로 성장할 것으로 예측

미국의 나노바디 시장은 2024년에 1억 5,280만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 3억 4,240만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 24.0%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 각각 분석 기간 동안에 13.2%와 16.4%의 CAGR로 성장할 것으로 예측됩니다. 유럽에서는 독일이 CAGR 약 14.4%로 성장할 것으로 예측됩니다.

세계의 나노바디 시장 - 주요 동향과 촉진요인 정리

나노바디가 치료제와 진단약으로 각광받는 이유는 무엇일까?

단일 도메인 항체라고도 알려진 나노바디는 낙타과 동물에서 유래한 독특한 항체 조각입니다. 기존의 항체와 달리 나노바디는 작고 안정적이며, 숨겨진 에피토프나 도달하기 어려운 에피토프에 결합할 수 있습니다. 컴팩트한 크기로 조직 침투성, 혈류로부터의 빠른 제거, 제조 용이성을 제공합니다. 이러한 특성은 종양학, 자가면역질환, 감염질환 치료, 영상 진단에 적용하기에 매우 매력적입니다.

또한, 구조가 단순하기 때문에 다특이적 포맷이나 융합 단백질로의 빠른 엔지니어링이 가능합니다. 나노바디는 흡입이나 국소 도포와 같은 기존과는 다른 경로로 전달할 수 있어 주사 가능한 생물학적 제제에 대한 대안이 될 수 있습니다. 제약 개발자들은 점점 더 표적화, 신속성, 비용 효율성이 높은 생물학적 제제를 찾고 있으며, 나노바디는 치료 개발 및 생체 내 진단 모두에서 차세대 도구로 자리매김하고 있습니다.

디자인 및 배송의 혁신은 나노바디의 가능성을 어떻게 확장하고 있는가?

단백질 공학 및 파지 디스플레이 라이브러리의 발전으로 나노바디 탐색 및 친화도 최적화가 향상되고 있습니다. 연구 개발자들은 낙타 면역에 직접 의존하지 않고도 합성 나노바디 라이브러리를 만들 수 있게 되어 개발 기간을 단축할 수 있게 되었습니다. 나노바디는 다가 형식으로 설계되어 결합 강도를 높이거나 여러 타겟에 동시에 작용할 수 있습니다.

약물전달에서 나노바디는 독소, 사이토카인 또는 방사성 핵종과 융합되어 질병 세포를 선택적으로 표적으로 삼습니다. 대장균이나 효모와 같은 미생물 시스템에서 발현시킬 수 있기 때문에 전체 길이의 단클론항체에 비해 생산비용이 절감됩니다. 나노바디-약물 복합체, 나노바디 기반 CAR-T 치료, 이중 특이성 포맷도 활발히 개발되고 있습니다. 이러한 발전은 전신 노출 및 면역 관련 독성을 최소화하면서 치료용 페이로드를 맞춤형으로 전달할 수 있게 해줍니다.

연구 및 임상 분야에서 수요를 주도하는 애플리케이션은 무엇인가?

진단학에서 나노바디는 바이오센서, 면역분석, 분자 이미징 도구에 널리 사용되고 있습니다. 가혹한 조건에서의 안정성으로 인해 현장 검사 및 현장 기반 감지 시스템에 적합합니다. 이미징에서 나노바디 기반 PET 트레이서는 기존 항체에 비해 더 높은 해상도와 더 빠른 클리어런스로 종양, 염증, 감염 부위를 실시간으로 가시화할 수 있습니다.

치료 측면에서는 염증성 질환, 암, 신경퇴행성 질환, COVID-19를 포함한 바이러스 감염에 대한 연구가 진행되고 있습니다. 종양학에서는 나노바디-약물 복합체 및 면역관문억제제가 초기 단계의 임상시험에서 유망한 것으로 나타났습니다. 신경학에서는 알츠하이머병이나 파킨슨병과 같은 질환에서 아밀로이드 플라크나 오접힘 단백질에 대한 표적 전달을 위해 혈액뇌장벽을 통과하는 나노바디의 능력이 평가되고 있습니다. 수의학 및 농업 생명공학도 질병 제어 및 검출을 위해 나노바디를 연구하고 있습니다.

나노바디 시장의 성장은 몇 가지 요인에 의해 주도됩니다...

나노바디 시장의 성장은 몇 가지 요인에 의해 주도되고 있습니다. 표적 생물학적 제제 및 정밀 진단에 대한 수요 증가는 작고 친화력이 높은 결합 분자의 개발을 촉진합니다. 합성생물학과 디스플레이 기술의 발전은 나노바디의 발견과 스크리닝을 가속화할 것입니다. 비용 효율적인 미생물 발현 시스템은 확장 가능한 생산을 지원합니다. 생물학적 제제의 임상 파이프라인과 규제 당국의 지원이 확대되고, 상업적 타당성이 높아집니다. 종양학, 신경퇴행성, 감염성 질환 연구에 대한 투자가 증가하여 새로운 응용 기회를 창출할 수 있습니다. 생명공학 기업, 학술 연구소, 제약 기업 간의 파트너십을 통해 제품 개발, 라이선싱, 시장 개척을 더욱 지원할 수 있습니다.

부문

유형(단특이적 유형, 다특이적 유형), 용도(후천성 혈전성 혈소판 감소성 자반증 용도, 호흡기세포융합바이러스 감염증 용도, 류마티스 관절염 용도, 전신홍반루푸스 용도, 종양 용도, 건선 용도, 골질환 용도, 기타 용도), 최종 용도(제약 기업·바이오테크놀러지 기업 최종 용도, 연구소 최종 용도, 기타 최종 용도)

조사 대상 기업 사례

  • AbCellera Biologics Inc.
  • Abiocenter
  • Alpaca Nanobodies Inc.
  • Amgen Inc.
  • BIOCYTOGEN Group
  • Bio-Rad Laboratories
  • Boehringer Ingelheim GmbH
  • Capralogics Inc.
  • Creative Biolabs
  • Cusabio
  • GenScript Biotech Corporation
  • Merck KGaA
  • Morphosys AG(Ablynx tech)
  • NanoTag Biotechnologies GmbH
  • Novartis AG
  • Proteintech Group, Inc.
  • PREGENE
  • QVQ Holding BV
  • Sanofi(Ablynx)
  • Thermo Fisher Scientific
  • Yiteng Pharmaceutical

AI 통합

Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 일반적인 LLM 및 업계별 SLM 쿼리를 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.08.25

Global Nanobodies Market to Reach US$1.5 Billion by 2030

The global market for Nanobodies estimated at US$561.0 Million in the year 2024, is expected to reach US$1.5 Billion by 2030, growing at a CAGR of 18.0% over the analysis period 2024-2030. Mono-Specific Type, one of the segments analyzed in the report, is expected to record a 19.5% CAGR and reach US$1.1 Billion by the end of the analysis period. Growth in the Multi-Specific Type segment is estimated at 14.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$152.8 Million While China is Forecast to Grow at 24.0% CAGR

The Nanobodies market in the U.S. is estimated at US$152.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$342.4 Million by the year 2030 trailing a CAGR of 24.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 13.2% and 16.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.4% CAGR.

Global Nanobodies Market - Key Trends & Drivers Summarized

Why Are Nanobodies Gaining Momentum in Therapeutics and Diagnostics?

Nanobodies, also known as single-domain antibodies, are a unique class of antibody fragments derived from camelid species. Unlike conventional antibodies, nanobodies are small, stable, and can bind to hidden or difficult-to-reach epitopes. Their compact size allows better tissue penetration, rapid clearance from the bloodstream, and ease of manufacturing. These properties make them highly attractive for applications in oncology, autoimmune diseases, infectious disease treatment, and diagnostic imaging.

Their structural simplicity also enables rapid engineering into multi-specific formats or fusion proteins. Nanobodies can be delivered through non-traditional routes such as inhalation or topical application, offering alternatives to injectable biologics. With pharmaceutical developers increasingly seeking targeted, fast-acting, and cost-effective biologics, nanobodies are positioned as next-generation tools in both therapeutic development and in vivo diagnostics.

How Is Innovation in Design and Delivery Expanding Nanobody Potential?

Advances in protein engineering and phage display libraries are improving nanobody discovery and affinity optimization. Researchers can now generate synthetic nanobody libraries without direct reliance on camelid immunization, accelerating development timelines. Nanobodies are being designed for multivalent formats, which enhance binding strength or engage multiple targets simultaneously-especially relevant in cancer immunotherapy and viral neutralization.

In drug delivery, nanobodies are being fused with toxins, cytokines, or radionuclides to selectively target diseased cells. Their ability to be expressed in microbial systems like E. coli or yeast reduces production costs compared to full-length monoclonal antibodies. Nanobody-drug conjugates, nanobody-based CAR-T therapies, and bispecific formats are also under active development. These advances allow tailored delivery of therapeutic payloads while minimizing systemic exposure and immune-related toxicity.

Which Applications Are Driving Demand Across Research and Clinical Settings?

In diagnostics, nanobodies are widely used in biosensors, immunoassays, and molecular imaging tools. Their stability under extreme conditions makes them suitable for point-of-care testing and field-based detection systems. In imaging, nanobody-based PET tracers enable real-time visualization of tumors, inflammation, or infectious sites with higher resolution and faster clearance compared to conventional antibodies.

Therapeutically, nanobodies are being investigated for inflammatory conditions, cancers, neurodegenerative diseases, and viral infections including COVID-19. In oncology, nanobody-drug conjugates and immune checkpoint inhibitors are showing promise in early-phase clinical trials. In neurology, their ability to cross the blood-brain barrier is under evaluation for targeted delivery to amyloid plaques or misfolded proteins in diseases like Alzheimer’s and Parkinson’s. Veterinary medicine and agricultural biotechnology are also exploring nanobodies for disease control and detection.

Growth in the Nanobodies Market Is Driven by Several Factors…

Growth in the nanobodies market is driven by several factors. Rising demand for targeted biologics and precision diagnostics encourages development of compact and high-affinity binding molecules. Advances in synthetic biology and display technologies accelerate nanobody discovery and screening. Cost-effective microbial expression systems support scalable production. Expanding clinical pipeline and regulatory support for biologics enhance commercial viability. Increased investment in oncology, neurodegeneration, and infectious disease research creates new application opportunities. Partnerships between biotech firms, academic labs, and pharmaceutical companies further support product development, licensing, and market expansion.

SCOPE OF STUDY:

The report analyzes the Nanobodies market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Mono-Specific Type, Multi-Specific Type); Application (Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application, Bone Disorders Application, Other Applications); End-Use (Pharma & Biotech Companies End-Use, Research Laboratories End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • AbCellera Biologics Inc.
  • Abiocenter
  • Alpaca Nanobodies Inc.
  • Amgen Inc.
  • BIOCYTOGEN Group
  • Bio-Rad Laboratories
  • Boehringer Ingelheim GmbH
  • Capralogics Inc.
  • Creative Biolabs
  • Cusabio
  • GenScript Biotech Corporation
  • Merck KGaA
  • Morphosys AG (Ablynx tech)
  • NanoTag Biotechnologies GmbH
  • Novartis AG
  • Proteintech Group, Inc.
  • PREGENE
  • QVQ Holding BV
  • Sanofi (Ablynx)
  • Thermo Fisher Scientific
  • Yiteng Pharmaceutical

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Nanobodies - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Targeted and Versatile Biotherapeutics Drives Interest in Nanobody-Based Drug Development
    • Superior Stability and Smaller Molecular Size of Nanobodies Throws Spotlight on Their Use in Hard-to-Reach Targets
    • Advancements in Immunotherapy and Oncology Research Propel Adoption of Nanobody-Based Modalities
    • Expansion of Bispecific and Multivalent Therapeutics Supports Use of Nanobodies in Complex Drug Design
    • Growing Research Activity in Autoimmune and Inflammatory Diseases Enhances Scope for Nanobody Applications
    • Increased Use of Nanobodies in Diagnostic Imaging and Molecular Tracers Strengthens Demand in Precision Medicine
    • OEM Collaborations With Academic Institutions Accelerate Innovation in Rare and Orphan Disease Therapeutics
    • Favorable Pharmacokinetics and Reduced Immunogenicity Drive Preference Over Conventional Antibodies
    • Emerging Interest in Inhalable and Topical Drug Delivery Formats Fuels Development of Nanobody-Based Treatments
    • Growth in CNS and Blood-Brain Barrier Research Encourages Nanobody Use for Neurological Conditions
    • Vaccine Development and Viral Neutralization Studies Highlight Role of Nanobodies in Infectious Disease Management
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Nanobodies Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Nanobodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Nanobodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Nanobodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Mono-Specific Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Mono-Specific Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Mono-Specific Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Multi-Specific Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Multi-Specific Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Multi-Specific Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Acquired Thrombotic Thrombocytopenic Purpura Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Acquired Thrombotic Thrombocytopenic Purpura Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Acquired Thrombotic Thrombocytopenic Purpura Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Respiratory Syncytial Virus Infection Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Respiratory Syncytial Virus Infection Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Respiratory Syncytial Virus Infection Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Rheumatoid Arthritis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Rheumatoid Arthritis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Rheumatoid Arthritis Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Systemic Lupus Erythematosus Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Systemic Lupus Erythematosus Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Systemic Lupus Erythematosus Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Oncology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Psoriasis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Psoriasis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Psoriasis Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Bone Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Bone Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Bone Disorders Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Pharma & Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Research Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Research Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: World 16-Year Perspective for Research Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Nanobodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 44: USA Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: USA 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: USA 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Canada 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Canada 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • JAPAN
    • Nanobodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Japan 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Japan 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CHINA
    • Nanobodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 71: China Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: China 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: China 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
    • TABLE 77: China Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: China Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: China 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • EUROPE
    • Nanobodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Nanobodies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Nanobodies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Nanobodies by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Europe 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Europe 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • FRANCE
    • Nanobodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 92: France Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: France 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: France 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
    • TABLE 98: France Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: France Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: France 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • GERMANY
    • Nanobodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Germany 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
    • TABLE 107: Germany Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Germany Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Germany 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: Italy 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
    • TABLE 116: Italy Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Italy Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: Italy 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Nanobodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 119: UK Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: UK 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
    • TABLE 125: UK Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: UK Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: UK 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Spain 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
    • TABLE 134: Spain Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Spain Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Spain 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Russia 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
    • TABLE 143: Russia Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Russia Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Russia 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Rest of Europe 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
    • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of Europe Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Rest of Europe 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Nanobodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Nanobodies by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Nanobodies by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Nanobodies by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Asia-Pacific 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
    • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Asia-Pacific Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Asia-Pacific 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Nanobodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Australia 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
    • TABLE 173: Australia Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Australia Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Australia 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • INDIA
    • Nanobodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 176: India Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: India 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
    • TABLE 179: India Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: India 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
    • TABLE 182: India Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: India Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: India 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: South Korea 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
    • TABLE 191: South Korea Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: South Korea Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: South Korea 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
    • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Asia-Pacific Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Asia-Pacific 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Nanobodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Nanobodies by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Nanobodies by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Nanobodies by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Latin America 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
    • TABLE 212: Latin America Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Latin America Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Latin America 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 220: Argentina 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
    • TABLE 221: Argentina Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Argentina Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 223: Argentina 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 229: Brazil 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
    • TABLE 230: Brazil Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Brazil Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 232: Brazil 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 238: Mexico 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
    • TABLE 239: Mexico Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Mexico Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 241: Mexico 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 247: Rest of Latin America 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
    • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Rest of Latin America Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 250: Rest of Latin America 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Nanobodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Nanobodies by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Nanobodies by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Nanobodies by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 259: Middle East 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
    • TABLE 260: Middle East Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Middle East Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 262: Middle East 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 268: Iran 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
    • TABLE 269: Iran Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Iran Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 271: Iran 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 277: Israel 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
    • TABLE 278: Israel Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Israel Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 280: Israel 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 286: Saudi Arabia 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
    • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Saudi Arabia Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 289: Saudi Arabia 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 295: UAE 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
    • TABLE 296: UAE Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: UAE Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 298: UAE 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 304: Rest of Middle East 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
    • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Rest of Middle East Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 307: Rest of Middle East 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AFRICA
    • Nanobodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 313: Africa 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
    • TABLE 314: Africa Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Africa Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 316: Africa 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제